4.7 Article

Acute effects of delayed-release hydrolyzed pine nut oil on glucose tolerance, incretins, ghrelin and appetite in healthy humans

期刊

CLINICAL NUTRITION
卷 40, 期 4, 页码 2169-2179

出版社

CHURCHILL LIVINGSTONE
DOI: 10.1016/j.clnu.2020.09.043

关键词

Free fatty acid receptors; Pine nut oil; Pinolenic acid; Incretins; Appetite; Oral glucose tolerance test

资金

  1. Danish Research Council for Strategic Research and Innovation Fund Denmark [11-116196, 0603-00452B]
  2. Odense University Hospital, The Region of Southern Denmark
  3. University of Southern Denmark
  4. Ingemann O. Bucks Fund

向作者/读者索取更多资源

The study found that PNO-FFA delivered to the small intestine by delayed-release capsules can increase GLP-1 levels and decrease ghrelin levels, leading to a reduction in appetite in the late postprandial state.
Bacground & aim: Pinolenic acid, a major component (similar to 20%) of pine nut oil, is a dual agonist of the free fatty acid receptors, FFA1 and FFA4, which may regulate release of incretins and ghrelin from the gut. Here, we investigated the acute effects of hydrolyzed pine nut oil (PNO-FFA), delivered to the small intestine by delayed-release capsules, on glucose tolerance, insulin, incretin and ghrelin secretion, and appetite. Methods: In two cross-over studies, we evaluated 3 g unhydrolyzed pine nut oil (PNO-TG) or 3 g PNO-FFA versus no oil in eight healthy, non-obese subjects (study 1), and 3 g PNO-FFA or 6 g PNO-FFA versus no oil in ten healthy, overweight/obese subjects (study 2) in both studies given in delayed-release capsules 30 min prior to a 4-h-oral glucose tolerance test (OGTT). Outcomes were circulating levels of glucose, insulin, GLP-1, GIP, ghrelin, appetite and gastrointestinal tolerability during OGTT. Results: Both 3 g PNO-FFA in study 1 and 6 g PNO-FFA in study 2 markedly increased GLP-1 levels (p < 0.001) and attenuated ghrelin levels (p < 0.001) during the last 2 h of the OGTT compared with no oil. In study 2, these effects of PNO-FFA were accompanied by an increased satiety and fullness (p < 0.03), and decreased prospective food consumption (p < 0.05). PNO-FFA caused only small reductions in glucose and insulin levels during the first 2 h of the OGTT. Conclusions: Our results provide evidence that PNO-FFA delivered to the small intestine by delayed-release capsules may reduce appetite by augmenting GLP-1 release and attenuating ghrelin secretion in the late postprandial state. (C) 2020 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据